CA2012295A1 - Derives de la pyrrolidine - Google Patents

Derives de la pyrrolidine

Info

Publication number
CA2012295A1
CA2012295A1 CA2012295A CA2012295A CA2012295A1 CA 2012295 A1 CA2012295 A1 CA 2012295A1 CA 2012295 A CA2012295 A CA 2012295A CA 2012295 A CA2012295 A CA 2012295A CA 2012295 A1 CA2012295 A1 CA 2012295A1
Authority
CA
Canada
Prior art keywords
het
formula
pyrrolidine derivatives
pyrrolidine
ch2s
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2012295A
Other languages
English (en)
Other versions
CA2012295C (fr
Inventor
Peter Edward Cross
Alexander Roderick Mackenzie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis International Pharmaceutical Ltd
Original Assignee
Peter Edward Cross
Alexander Roderick Mackenzie
Pfizer Limited
Pfizer Inc.
Novartis International Pharmaceutical Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10653525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2012295(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Peter Edward Cross, Alexander Roderick Mackenzie, Pfizer Limited, Pfizer Inc., Novartis International Pharmaceutical Ltd. filed Critical Peter Edward Cross
Publication of CA2012295A1 publication Critical patent/CA2012295A1/fr
Application granted granted Critical
Publication of CA2012295C publication Critical patent/CA2012295C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
CA002012295A 1989-03-17 1990-03-15 Derives de la pyrrolidine Expired - Lifetime CA2012295C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898906166A GB8906166D0 (en) 1989-03-17 1989-03-17 Therapeutic agents
GB8906166.7 1989-03-17

Publications (2)

Publication Number Publication Date
CA2012295A1 true CA2012295A1 (fr) 1990-09-17
CA2012295C CA2012295C (fr) 1996-11-12

Family

ID=10653525

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002012295A Expired - Lifetime CA2012295C (fr) 1989-03-17 1990-03-15 Derives de la pyrrolidine

Country Status (37)

Country Link
US (1) US5096890B1 (fr)
EP (1) EP0388054B1 (fr)
JP (2) JPH0764809B2 (fr)
KR (2) KR920008166B1 (fr)
CN (1) CN1023007C (fr)
AT (1) ATE96783T1 (fr)
AU (1) AU614224B2 (fr)
BA (1) BA98300A (fr)
CA (1) CA2012295C (fr)
CL (1) CL2003002756A1 (fr)
CY (2) CY1812A (fr)
CZ (1) CZ280053B6 (fr)
DD (1) DD292911A5 (fr)
DE (2) DE122005000022I2 (fr)
DK (1) DK0388054T3 (fr)
EG (1) EG18951A (fr)
ES (1) ES2060020T3 (fr)
FI (1) FI95573C (fr)
GB (1) GB8906166D0 (fr)
HK (1) HK130294A (fr)
HU (2) HU217433B (fr)
IE (1) IE62515B1 (fr)
IL (1) IL93694A (fr)
LU (1) LU91161I2 (fr)
MX (1) MX9319890A (fr)
MY (1) MY105527A (fr)
NL (1) NL300191I2 (fr)
NO (2) NO176316C (fr)
NZ (1) NZ232958A (fr)
PL (1) PL164136B1 (fr)
PT (1) PT93443B (fr)
RU (2) RU1833374C (fr)
SG (1) SG143394G (fr)
SK (1) SK278434B6 (fr)
UA (1) UA18263A (fr)
YU (1) YU47587B (fr)
ZA (1) ZA901982B (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8825505D0 (en) * 1988-11-01 1988-12-07 Pfizer Ltd Therapeutic agents
US5932594A (en) * 1988-11-01 1999-08-03 Pfizer, Inc. Muscarinic receptor antagonists
GB8928042D0 (en) * 1989-12-12 1990-02-14 Pfizer Ltd Muscarinic receptor antagonists
US5607950A (en) * 1990-01-06 1997-03-04 Pfizer Inc. Muscarinic receptor antagonists
US5486527A (en) * 1990-01-06 1996-01-23 Pfizer Inc. Anticholinergic agents
WO1993022309A1 (fr) * 1992-04-23 1993-11-11 Merrell Dow Pharmaceuticals Inc. 4-imidomethyl-1-[2'phenyl-2'oxoethyl-] piperidines en tant qu'inhibiteurs des recepteurs 5ht2 a la serotonine, leur preparation et leurs applications therapeutiques
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness
US6017931A (en) * 1994-03-01 2000-01-25 Fmc Corporation Insecticidal compositions containing n-(substituted phenylmethyl)-4-[bis(substituted phenyl)methyl]piperidines
US5639763A (en) * 1994-03-01 1997-06-17 Fmc Corporation Insecticidal N-(substituted arylmethyl)-4-[bis(substituted phenyl)methyl]piperidines
BR9508436A (pt) * 1994-07-27 1998-07-14 Procter & Gamble Dihidro benzofurando e compostos correlacionados úteis como agentes anti-inflamatórios
US5674891A (en) * 1994-07-27 1997-10-07 The Procter & Gamble Company Dihydrobenzothiophene compounds useful as anti-inflammatory agents
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US5672620A (en) * 1996-02-01 1997-09-30 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
US5684031A (en) * 1996-02-01 1997-11-04 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
WO1998024431A1 (fr) * 1996-12-02 1998-06-11 Kyorin Pharmaceutical Co., Ltd. Nouveaux derives de pyrrolidine n-substitues et procede de preparation de ces derives
US6131129A (en) * 1997-07-30 2000-10-10 Sony Corporation Of Japan Computer system within an AV/C based media changer subunit providing a standarized command set
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US6653339B2 (en) 2001-08-15 2003-11-25 Pfizer Inc. Method of treating irritable bowel syndrome
ATE418534T1 (de) * 2001-10-26 2009-01-15 Pharmacia & Upjohn Co Llc Quaternäre ammoniumverbindungen und deren verwendung als antimuscarinische wirkstoffe
SE0103668D0 (sv) * 2001-11-02 2001-11-02 Astrazeneca Ab Method for the treatment of overactive blader
EP1441706A2 (fr) * 2001-11-05 2004-08-04 Pharmacia & Upjohn Company Aerosol antimuscarinique
GB0129962D0 (en) * 2001-12-14 2002-02-06 Pfizer Ltd Method of treatment
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
WO2004004629A2 (fr) 2002-07-08 2004-01-15 Ranbaxy Laboratories Limited Derives d'azabicyclo[3.1.0]hexanes 3,6-disubstitues utiles comme antagonistes des recepteurs muscariniques
ATE396969T1 (de) 2002-07-31 2008-06-15 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo (3.1.0)hexanderivate, die sich als muscarinrezeptorantagonisten eignen
WO2004014363A1 (fr) 2002-08-09 2004-02-19 Ranbaxy Laboratories Limited Derives d'azabicyclo[3.1.0] hexane 3,6-disubstitues, utiles en tant qu'agonistes de recepteurs muscariniques
JP2006501236A (ja) 2002-08-23 2006-01-12 ランバクシー ラボラトリーズ リミテッド ムスカリン性レセプター拮抗薬としてのフルオロおよびスルホニルアミノ含有３，６−二置換アザビシクロ（３．１．０）ヘキサン誘導体
TW200412945A (en) * 2002-10-25 2004-08-01 Upjohn Co Quaternary ammonium compounds
TWI295669B (en) * 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
US7232835B2 (en) 2002-12-10 2007-06-19 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists
EP1583741A1 (fr) 2002-12-23 2005-10-12 Ranbaxy Laboratories, Limited Derives de 1-substitues-3-pyrrolidines comme antagonistes de recepteurs muscariniques
US7501443B2 (en) 2002-12-23 2009-03-10 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
US7517905B2 (en) 2003-04-09 2009-04-14 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004089363A1 (fr) 2003-04-10 2004-10-21 Ranbaxy Laboratories Limited Derives d’azabicyclo hexanes substitues en tant qu’antagonistes des recepteurs muscariniques
EP1615887A1 (fr) 2003-04-10 2006-01-18 Ranbaxy Laboratories, Ltd. Derives d'azabicyclo hexanes en tant qu'antagonistes des recepteurs muscariniques
AU2004228452A1 (en) 2003-04-11 2004-10-21 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
EP1622606A1 (fr) * 2003-04-15 2006-02-08 Pharmacia & Upjohn Company LLC Composes d'ammonium quaternaire et leur utilisation comme agents antimuscariniques
WO2004091597A2 (fr) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Procede pour traiter le syndrome du colon irritable
CA2522666A1 (fr) * 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Polytherapies
TW200510298A (en) * 2003-06-13 2005-03-16 Theravance Inc Substituted pyrrolidine and related compounds
US7368463B2 (en) 2003-07-11 2008-05-06 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
EP1725525A1 (fr) * 2004-03-11 2006-11-29 Theravance, Inc. Composes biphenyle convenant en tant qu'antagonistes du recepteur muscarinique
EP1723142A1 (fr) * 2004-03-11 2006-11-22 Theravance, Inc. Composes de diphenylmethyle, antagonistes du recepteur muscarinique
WO2005092341A1 (fr) * 2004-03-22 2005-10-06 Ranbaxy Laboratories Limited Therapie combinee destinee a reduire les symptomes des voies urinaires
WO2007045979A1 (fr) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions pharmaceutiques d'antagonistes du recepteur muscarinique
WO2007076158A2 (fr) * 2005-12-27 2007-07-05 Teva Pharmaceutical Industries Ltd. Procedes de preparation de bromhydrate de darifenacine
AR062676A1 (es) * 2006-09-07 2008-11-26 Medichem Sa Procedimiento mejorado para preparar compuestos de pirrolidina 1,3-disustituidas
WO2008076269A2 (fr) * 2006-12-13 2008-06-26 Gilead Sciences, Inc. MONOPHOSPHATES UTILISÉS COMME PROMÉDICAMENTS MUTUELS D'ANTAGONISTES DES RÉCEPTEURS MUSCARINIQUES ET DE β-AGONISTES DANS LE TRAITEMENT DE LA B.P.C.O. ET DE LA BRONCHITE CHRONIQUE
WO2008100651A2 (fr) * 2007-01-05 2008-08-21 Dr. Reddy's Laboratories Ltd. Préparation de darifénacine et ses sels
JP5528817B2 (ja) * 2007-02-23 2014-06-25 セラヴァンス， インコーポレーテッド ムスカリン受容体アンタゴニストとして有用な第四級アンモニウムジフェニルメチル化合物
WO2008126106A2 (fr) * 2007-04-16 2008-10-23 Manne Satyanarayana Reddy Procédés nouveaux et perfectionnés pour la préparation d'intermédiaires de darifénacine, de la darifénacine et de ses sels pharmaceutiquement acceptables
US20100204296A1 (en) * 2007-06-08 2010-08-12 Actavis Group Ptc Ehf Novel Polymorphs of Darifenacin Free Base and its Hydrobromide Salt
WO2008152497A1 (fr) * 2007-06-15 2008-12-18 Medichem, S.A. Procédé de détermination de la pureté énantiomérique de la darifénacine et de ses intermédiaires
US20090005431A1 (en) * 2007-06-30 2009-01-01 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
AR068322A1 (es) * 2007-07-13 2009-11-11 Medichem Sa Forma amorfa de hidrobromuro de darifenacina y procedimientos para su preparacion
CZ300895B6 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
WO2009125430A2 (fr) * 2008-03-17 2009-10-15 Matrix Laboratoires Limited Procédé perfectionné pour la fabrication de darifénacine
CN101983187A (zh) * 2008-04-02 2011-03-02 株式会社钟化 (s)-3-(1-氰基-1，1-二苯基甲基)吡咯烷的制备方法
WO2010032225A2 (fr) * 2008-09-22 2010-03-25 Watson Pharma Private Limited Procédé de préparation de darifénacine et intermédiaires utilisés dans le cadre dudit procédé
EP2236509A1 (fr) 2009-04-01 2010-10-06 Ragactives, S.L. Méthode de préparation de dérivés de la pyrrolidine 1,3 substituée
SG176056A1 (en) 2009-05-15 2011-12-29 Redx Pharma Ltd Redox drug derivatives
WO2011070419A1 (fr) 2009-12-10 2011-06-16 Aurobindo Pharma Limited Procédé perfectionné pour la préparation de bromhydrate de darifénacine
JP5812500B2 (ja) 2010-04-30 2015-11-17 メルク・シャープ・エンド・ドーム・コーポレイション 新規なβ３アドレナリン作動性受容体アゴニスト
CN101857581A (zh) * 2010-06-22 2010-10-13 浙江美诺华药物化学有限公司 一种制备达非那新中间体5-(2-溴乙基)-2,3-二氢-1-苯并呋喃的方法
WO2011161504A1 (fr) 2010-06-23 2011-12-29 Micro Labs Limited Formulations à libération prolongée contenant de la darifénacine ou des sels pharmaceutiquement acceptables de celle-ci

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1057145A (en) * 1963-08-16 1967-02-01 Bellon Labor Sa Roger Phenylcyclohexylacetonitrile derivatives
US4002766A (en) * 1974-12-26 1977-01-11 A. H. Robins Company, Incorporated Antiarrhythmia methods
US4242261A (en) * 1979-07-19 1980-12-30 A. H. Robins Company, Inc. Production of methylene-cycloamines
IL76583A (en) * 1984-10-19 1988-08-31 Robins Co Inc A H 1-(aminoalkyl)-alpha'alpha-diaryl pyrrolidinyl,piperidino and homopiperidino acetamides and acetonitriles and pharmaceutical compositions containing them
US4594343A (en) * 1984-10-19 1986-06-10 Shanklin Jr James R 1-[(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-α,α-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles
EP0235463A3 (fr) * 1985-12-20 1990-01-17 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) Arylalkyl et arylalkylène piperidines substitués sur l'azote utilisés comme agents antihistaminiques cardiovasculaires et antisécrétion
IL78939A (en) * 1986-01-17 1990-04-29 Robins Co Inc A H Pharmaceutical compositions containing n-substituted arylalkyl-and arylalkylene-piperidines and tetrahydropyridines and certain such novel compounds

Also Published As

Publication number Publication date
CN1023007C (zh) 1993-12-08
CZ280053B6 (cs) 1995-10-18
EP0388054B1 (fr) 1993-11-03
AU614224B2 (en) 1991-08-22
HK130294A (en) 1994-12-02
GB8906166D0 (en) 1989-05-04
DE122005000022I1 (de) 2005-08-04
CN1045580A (zh) 1990-09-26
FI95573B (fi) 1995-11-15
UA18263A (uk) 1997-12-25
JPH02282360A (ja) 1990-11-19
ATE96783T1 (de) 1993-11-15
NL300191I2 (nl) 2005-08-01
KR900014367A (ko) 1990-10-23
NL300191I1 (nl) 2005-07-01
DD292911A5 (de) 1991-08-14
CY2005005I1 (el) 2010-07-28
PT93443B (pt) 1996-02-29
FI901333A0 (fi) 1990-03-16
JPH0764809B2 (ja) 1995-07-12
NO2005008I2 (no) 2006-11-27
YU47587B (sh) 1995-10-24
HU211640A9 (en) 1995-12-28
DK0388054T3 (da) 1993-12-06
EG18951A (en) 1994-03-30
NO901241D0 (no) 1990-03-16
AU5140290A (en) 1990-09-20
IL93694A (en) 1994-08-26
CY1812A (en) 1995-10-20
SK129590A3 (en) 1997-05-07
KR920008166B1 (ko) 1992-09-24
CZ129590A3 (en) 1995-05-17
MY105527A (en) 1994-10-31
US5096890A (en) 1992-03-17
PL164136B1 (pl) 1994-06-30
ES2060020T3 (es) 1994-11-16
HU217433B (hu) 2000-01-28
CY2005005I2 (el) 2010-07-28
DE122005000022I2 (de) 2006-02-02
NO176316C (no) 1995-03-15
DE69004302T2 (de) 1994-02-24
DE69004302D1 (de) 1993-12-09
PT93443A (pt) 1990-11-07
IL93694A0 (en) 1990-12-23
MX9319890A (es) 1993-08-01
US5096890B1 (en) 1995-03-28
ZA901982B (en) 1991-10-30
YU52790A (sh) 1992-07-20
IE900955L (en) 1990-09-17
NZ232958A (en) 1992-05-26
SG143394G (en) 1995-01-13
NO176316B (no) 1994-12-05
HUT58313A (en) 1992-02-28
CL2003002756A1 (es) 2005-02-11
EP0388054A1 (fr) 1990-09-19
RU1833374C (ru) 1993-08-07
FI95573C (fi) 1996-02-26
KR960015142B1 (ko) 1996-11-01
CA2012295C (fr) 1996-11-12
JPH07149640A (ja) 1995-06-13
NO2005008I1 (en) 2005-04-11
IE62515B1 (en) 1995-02-08
SK278434B6 (en) 1997-05-07
HU901580D0 (en) 1990-06-28
LU91161I2 (fr) 2005-06-13
BA98300A (bs) 2001-09-14
NO901241L (no) 1990-09-18
RU2015965C1 (ru) 1994-07-15

Similar Documents

Publication Publication Date Title
CA2012295A1 (fr) Derives de la pyrrolidine
KR950700309A (ko) 피페리디닐 티아시클릭 유도체(Piperidinyl Thiacyclic Derivatives)
ATE102183T1 (de) Muscarin-rezeptor-antagonisten.
DK497888D0 (da) N-(substitueret alkyliden)-1,2,3,4-tetrahydro-9-a cridinaminer, deres fremstilling og anvendelse
ATE101599T1 (de) Muscarin-rezeptor-antagonisten.
CA2177602A1 (fr) Derives n-substitues d'azabicycloalcane, preparation et utilisation de ces derives

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry